We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease.
- Authors
O'Hagan, Shaun; Galway, Niamh; Shields, Michael D; Mallett, Peter; Groves, Helen E
- Abstract
Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific "high-risk" populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.
- Subjects
PALIVIZUMAB; RESPIRATORY syncytial virus; BRONCHOPULMONARY dysplasia; CONGENITAL heart disease; LENGTH of stay in hospitals; BRONCHIOLITIS
- Publication
Drug, Healthcare & Patient Safety, 2023, Vol 15, p103
- ISSN
1179-1365
- Publication type
Article
- DOI
10.2147/DHPS.S348727